1/11
07:40 pm
anab
What Investors Should Know About a $163K AnaptysBio Insider Sale [Yahoo! Finance]
Medium
Report
What Investors Should Know About a $163K AnaptysBio Insider Sale [Yahoo! Finance]
1/11
06:56 pm
anab
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally [Yahoo! Finance]
Medium
Report
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally [Yahoo! Finance]
1/10
02:18 am
anab
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Medium
Report
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
1/9
06:10 am
anab
AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/9
04:18 am
anab
AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute [Yahoo! Finance]
Low
Report
AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute [Yahoo! Finance]
1/8
07:18 pm
anab
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty [Yahoo! Finance]
Low
Report
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty [Yahoo! Finance]
1/8
07:02 pm
anab
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary [Yahoo! Finance]
Low
Report
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary [Yahoo! Finance]
1/8
06:00 pm
anab
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
Low
Report
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
1/7
04:06 am
anab
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at UBS Group AG.
Low
Report
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at UBS Group AG.
1/6
04:15 pm
anab
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/19
03:13 pm
anab
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving [Yahoo! Finance]
Low
Report
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving [Yahoo! Finance]
12/18
09:09 am
anab
AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
06:02 am
anab
AnaptysBio (NASDAQ:ANAB) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/11
08:44 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
11/26
03:14 pm
anab
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]
Low
Report
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]
11/25
04:56 pm
anab
Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]
Low
Report
Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]
11/25
04:15 pm
anab
Anaptys Announces Participation in December Investor Conferences
Low
Report
Anaptys Announces Participation in December Investor Conferences
11/24
08:43 am
anab
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
11/24
08:06 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
11/21
07:04 pm
anab
Anaptys Announces $100 Million Stock Repurchase Plan [Yahoo! Finance]
Medium
Report
Anaptys Announces $100 Million Stock Repurchase Plan [Yahoo! Finance]
11/21
09:12 am
anab
AnaptysBio shares tumble after legal fight with GSK over cancer drug license [Yahoo! Finance]
High
Report
AnaptysBio shares tumble after legal fight with GSK over cancer drug license [Yahoo! Finance]
11/21
04:01 am
anab
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary [Yahoo! Finance]
Medium
Report
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary [Yahoo! Finance]
11/21
04:00 am
anab
Anaptys Announces $100 Million Stock Repurchase Plan
High
Report
Anaptys Announces $100 Million Stock Repurchase Plan
11/21
03:50 am
anab
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
High
Report
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
11/20
03:23 am
anab
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation [Yahoo! Finance]
Low
Report
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation [Yahoo! Finance]